← Leaderboards
Cliona M Rooney
Baylor College Of Medicine
$13,445,584
Attributed
$18,920,937
Total exposure
22
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,524,404 · 23
By mechanism
P01$20,574,852 · 16
P50$5,071,422 · 4
T32$1,638,510 · 1
R01$1,239,620 · 2
Top collaborators
- Helen E Heslop35 shared
- Ignatia B Van Den Veyver4 shared
- Malcolm K Brenner1 shared
- Stephen Gottschalk1 shared
- Ann M. Leen1 shared
- Zhuyong Mei1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Helen E Heslop$25,308,937
- Malcolm K Brenner$13,204,649
- Stephen Gottschalk$13,145,706
- Barbara Savoldo$8,193,565
- Ann M. Leen$2,736,030
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsT Cell TherapyT-LymphocyteIn VivoTumorSafetyTumor AntigensClinical ResearchToxic EffectResearch PersonnelProgramsMalignant NeoplasmsHuman Herpesvirus 4Clinical TrialsAntigensImmunotherapyResponseImmuneEnvironmentLymphomaResistanceEnsureViral AntigensNeoplastic Cell
Grant awards (73)
Project 3: Increasing the potency and accessibility of EBVSTs for the treatment of Lymphoma$319,603
P50 · FY2025 · CA · contact PI
Project 3: Increasing the potency and accessibility of EBVSTs for the treatment of Lymphoma$315,594
P50 · FY2024 · CA · contact PI
Project 3: Increasing the potency and accessibility of EBVSTs for the treatment of Lymphoma$350,699
P50 · FY2023 · CA · contact PI
Project 3: Increasing the potency and accessibility of EBVSTs for the treatment of Lymphoma$311,474
P50 · FY2022 · CA · contact PI
Overcoming Tumor Evasion in EBV+ve Lymphomas$259,749
P50 · FY2021 · CA · contact PI
Overcoming Tumor Evasion in EBV+ve Lymphomas$267,813
P50 · FY2020 · CA · contact PI
Training Program in Translational Biology and Molecular Medicine$379,882
T32 · FY2019 · GM
Overcoming Tumor Evasion in EBV+ve Lymphomas$320,699
P50 · FY2019 · CA · contact PI
Training Program in Translational Biology and Molecular Medicine$424,169
T32 · FY2018 · GM
Overcoming Tumor Evasion in EBV+ve Lymphomas$279,303
P50 · FY2018 · CA · contact PI
ENHANCING T CELL THERAPY OF CANCER$1,932,287
P01 · FY2017 · CA
CELL AND VECTOR PRODUCTION$492,025
P01 · FY2017 · CA
Training Program in Translational Biology and Molecular Medicine$419,504
T32 · FY2017 · GM
VACCINATION TO ENHANCE T CELL IMMUNOTHERAPY$295,519
P01 · FY2017 · CA
CHIMERIC T CELLS TARGETING NEUROBLASTOMA$295,506
P01 · FY2017 · CA
Overcoming Tumor Evasion in EBV+ve Lymphomas$268,356
P50 · FY2017 · CA · contact PI
Improving T Cell Therapies for Nasopharyngeal Cancer$264,138
P01 · FY2017 · CA
ENGINEERING T CELLS FOR PANCREATIC CANCER$254,484
P01 · FY2017 · CA
CLINICAL RESEARCH AND BIOSTATISTICS CORE$232,807
P01 · FY2017 · CA
ADMINISTRATIVE CORE$97,808
P01 · FY2017 · CA
Enhancing T Cell Therapy of Cancer$1,932,287
P01 · FY2016 · CA
CELL AND VECTOR PRODUCTION$492,027
P01 · FY2016 · CA
Training Program in Translational Biology and Molecular Medicine$414,955
T32 · FY2016 · GM
VACCINATION TO ENHANCE T CELL IMMUNOTHERAPY$295,517
P01 · FY2016 · CA
CHIMERIC T CELLS TARGETING NEUROBLASTOMA$295,508
P01 · FY2016 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer$264,136
P01 · FY2016 · CA
ENGINEERING T CELLS FOR PANCREATIC CANCER$254,482
P01 · FY2016 · CA
CLINICAL RESEARCH AND BIOSTATISTICS CORE$232,809
P01 · FY2016 · CA
BUILDING ON SUCCESSFUL T CELL THERAPY FOR EBV LYMPHOMA$214,761
P50 · FY2016 · CA · contact PI
ADMINISTRATIVE CORE$97,808
P01 · FY2016 · CA
Enhancing T Cell Therapy of Cancer$1,932,287
P01 · FY2015 · CA
CELL AND VECTOR PRODUCTION$492,025
P01 · FY2015 · CA
VACCINATION TO ENHANCE T CELL IMMUNOTHERAPY$295,515
P01 · FY2015 · CA
CHIMERIC T CELLS TARGETING NEUROBLASTOMA$295,506
P01 · FY2015 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer$264,141
P01 · FY2015 · CA
ENGINEERING T CELLS FOR PANCREATIC CANCER$254,484
P01 · FY2015 · CA
CLINICAL RESEARCH AND BIOSTATISTICS CORE$232,808
P01 · FY2015 · CA
BUILDING ON SUCCESSFUL T CELL THERAPY FOR EBV LYMPHOMA$217,047
P50 · FY2015 · CA · contact PI
ADMINISTRATIVE CORE$97,808
P01 · FY2015 · CA
Enhancing T Cell Therapy of Cancer$1,874,319
P01 · FY2014 · CA
CELL AND VECTOR PRODUCTION$478,502
P01 · FY2014 · CA
CHIMERIC T CELLS TARGETING NEUROBLASTOMA$287,387
P01 · FY2014 · CA
VACCINATION TO ENHANCE T CELL IMMUNOTHERAPY$282,534
P01 · FY2014 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer$256,879
P01 · FY2014 · CA
ENGINEERING T CELLS FOR PANCREATIC CANCER$247,486
P01 · FY2014 · CA
CLINICAL RESEARCH AND BIOSTATISTICS CORE$226,411
P01 · FY2014 · CA
BUILDING ON SUCCESSFUL T CELL THERAPY FOR EBV LYMPHOMA$214,762
P50 · FY2014 · CA · contact PI
ADMINISTRATIVE CORE$95,120
P01 · FY2014 · CA
Enhancing T Cell Therapy of Cancer$1,932,287
P01 · FY2013 · CA
Cell and Vector Production$493,302
P01 · FY2013 · CA
Chimeric T Cells Targeting Neuroblastoma$296,275
P01 · FY2013 · CA
Vaccination to Enhance T cell Immunotherapy$291,271
P01 · FY2013 · CA · contact PI
Improving T Cell Therapies for Nasopharyngeal Cancer$264,825
P01 · FY2013 · CA
Engineering T Cells for Pancreatic Cancer$255,140
P01 · FY2013 · CA
Clinical Research and Biostatistics Core$233,412
P01 · FY2013 · CA
BUILDING ON SUCCESSFUL T CELL THERAPY FOR EBV LYMPHOMA$214,878
P50 · FY2013 · CA · contact PI
Administrative Core$98,062
P01 · FY2013 · CA
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE$271,113
P01 · FY2012 · CA · contact PI
BUILDING ON SUCCESSFUL T CELL THERAPY FOR EBV LYMPHOMA$228,471
P50 · FY2012 · CA · contact PI
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE$271,819
P01 · FY2011 · CA · contact PI
Immunotherapy for Hodgkin's Disease$236,989
P50 · FY2011 · CA · contact PI
Immunotherapy for Hodgkin's Disease$285,478
P50 · FY2010 · CA · contact PI
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE$280,910
P01 · FY2010 · CA · contact PI
Immunotherapy for Hodgkin's Disease$287,534
P50 · FY2009 · CA · contact PI
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE$276,022
P01 · FY2009 · CA · contact PI
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE$268,054
P01 · FY2008 · CA · contact PI
Immunotherapy for Hodgkin's Disease$245,785
P50 · FY2008 · CA · contact PI
Immunotherapy for Hodgkin's Disease$232,427
P50 · FY2007 · CA · contact PI
CYTOTOXIC T CELL TRANSFER FOR THERAPY OF EBV LYMPHOMA$370,707
R01 · FY2002 · CA
Overcoming Tumor Immune Evasion Strategies in Hodgkin's Lymphoma$0
P01 · FY2002 · CA
CYTOTOXIC T CELL TRANSFER FOR THERAPY OF EBV LYMPHOMA$355,931
R01 · FY2001 · CA
CYTOTOXIC T CELL TRANSFER FOR THERAPY OF EBV LYMPHOMA$350,358
R01 · FY2000 · CA
TREATMENT OF HODGKIN DISEASE WITH GENE MARKED CTL$162,624
R01 · FY2000 · CA